The opportunity to redefine the treatment of major diseases is what drives everyone at Vertex. Our development portfolio represents the fruit of these efforts. Spend some time here and look around. Click on the pipeline chart to get information on our development programs and links to selected published articles. Go further and see how, just maybe, disease challenges may be overcome with innovation.

VX-509
(Inflammatory Diseases)

VX-509 is a novel Janus kinase 3 (JAK3) inhibitor currently in Phase 1a clinical development for the potential treatment of multiple immune-mediated inflammatory diseases. Based on in vitro data, VX-509 appears to be a potent and selective inhibitor of JAK3. Vertex holds worldwide development and commercial rights to VX-509.